Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association Between Cholinesterase Inhibitor-Overactive Bladder Antimuscarinic Prescribing Cascade and Risk of Delirium and Falls Among Individuals Living With Dementia.

Journal of the American Geriatrics Society·2026

Same author

Community pharmacists' pneumococcal vaccine knowledge and perceived barriers to vaccination.

Vaccine·2025

Same author

Human microbiome: Impact of newly approved treatments on C. difficile infection.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024

Same author

Continuous Low-Intensity Ultrasound Improves Cartilage Repair in Rabbit Model of Subchondral Injury.

Tissue engineering. Part A·2024

Same author

Associations Between Opioid Prescriptions and Use of Hospital-Based Services Among US Adults with Longstanding Physical Disability or Inflammatory Conditions Compared to Other Adults in the Medical Expenditure Panel Survey, 2010-2015.

Journal of pain research·2023

Same author

Response to Almenoff.

The American journal of gastroenterology·2023

Search research articles

Related Experiment Video

Updated: May 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Extended-release mesalamine granules for ulcerative colitis.

Bryan L Love¹, April D Miller

¹Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy-University of South Carolina Campus, Columbia, SC, USA. loveb@sccp.sc.edu

The Annals of Pharmacotherapy

|November 2, 2012

Summary

Extended-release mesalamine granules effectively maintain remission in mild to moderate ulcerative colitis (UC). This treatment is well-tolerated, with further research needed for optimal induction therapy.

Related Experiment Videos

Last Updated: May 17, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Area of Science:

Gastroenterology
Pharmacology

Background:

Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
5-aminosalicylate agents are preferred for UC remission induction and maintenance.
Mesalamine granules are available in encapsulated (US) and non-encapsulated (Europe) forms.

Purpose of the Study:

To evaluate the efficacy and safety of extended-release mesalamine granules for maintaining remission in ulcerative colitis.
To synthesize current evidence on mesalamine granule use in UC management.

Main Methods:

Systematic literature search of MEDLINE and bibliographies (1990-June 2012).
Inclusion of English-language studies on human use of extended-release mesalamine granules.
Evaluation of randomized, double-blind, placebo-controlled trials for maintenance efficacy.

Main Results:

Mesalamine granules demonstrated efficacy in achieving clinical and endoscopic remission for induction.
Two pivotal trials showed a higher relapse-free rate at 6 months with encapsulated mesalamine granules compared to placebo.
The most common adverse effects were headache, nausea, and upper respiratory infections, indicating good tolerability.

Conclusions:

Extended-release mesalamine granules are supported by current evidence for maintaining remission in mild to moderate UC.
Additional research is required to determine optimal dosing and regimens for encapsulated mesalamine granules in UC induction therapy.